Skip to main content
Eledon Pharmaceuticals, Inc. logo

Eledon Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · ELDN ISIN · US67011N2045 LEI · 549300S17CAM13O43606 US Professional, scientific and technical activities
Open in API
Filings indexed 585 across all filing types
Latest filing 2014-09-12 Regulatory Filings
Country US United States of America
Listing US ELDN

About Eledon Pharmaceuticals, Inc.

https://eledon.com/

Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing immune-modulating therapies for organ transplantation and autoimmune diseases. The company's mission, "One Transplant for Life," focuses on improving transplant longevity and the quality of life for recipients. Its lead product candidate, tegoprubart, is an anti-CD40 Ligand (CD40L) antibody designed to regulate the immune system to prevent organ rejection. Eledon has completed a Phase 2 clinical trial evaluating tegoprubart in kidney transplant recipients and is advancing the compound into late-stage development. The company is also exploring tegoprubart's potential in other applications, including liver transplantation and xenotransplantation.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter from Tokai Pharmaceuticals, Inc. to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-1. It references the Registration Statement and Rule 461 under the Securities Act of 1933. The document is a correspondence related to a regulatory filing process, specifically about the timing of the effectiveness of a registration statement for securities offering. It does not contain financial statements, audit information, or detailed report content. The document length is short (1946 characters) and is a formal request letter, not a report or presentation. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2014-09-12 English
AUTO-GENERATED PAPER DOCUMENT
Regulatory Filings
2014-09-12 English
FORM 8-A12B
Regulatory Filings Classification · 100% confidence The document is a Form 8-A12B filed with the SEC for the registration of certain classes of securities pursuant to Section 12(b) or 12(g) of the Securities Exchange Act of 1934. It describes the registration of common stock on NASDAQ and references a prior S-1 registration statement. The document is a regulatory filing related to securities registration, not a financial report, earnings release, or management discussion. It is a formal SEC filing for registration purposes, which fits best under the category of Regulatory Filings (RNS). The document length is short (2702 characters) and it is not an announcement of a report but the filing itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2014-09-12 English
S-1/A AMENDMENT NO. 1
Capital/Financing Update Classification · 100% confidence The document is an Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC, dated September 2, 2014, for Tokai Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933, used for initial public offerings (IPOs) or other securities offerings. The text includes details about the offering, underwriting, risk factors, business overview, management, and financial data. This type of filing is a capital markets document related to the company's fundraising and securities issuance. It is not an annual report, earnings release, or other financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2014-09-02 English
Regulatory Filings 2014
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the Securities and Exchange Commission (SEC) regarding a Registration Statement on Form S-1 filed by Tokai Pharmaceuticals, Inc. The letter provides additional confidential information about the anticipated price range for the company's initial public offering (IPO). It discusses valuation factors, clinical trial data, and the impact of the IPO on the company's financial position. The document is a correspondence related to the registration and offering process, not a financial report or earnings release. It does not contain financial statements or detailed financial analysis but rather supplemental information for regulatory review. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2014-08-26 English
FORM S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, dated August 11, 2014, for Tokai Pharmaceuticals, Inc. It is a registration statement under the Securities Act of 1933 for an initial public offering (IPO) of common stock. The text includes detailed information typical of an S-1 filing such as company overview, risk factors, use of proceeds, capitalization, dilution, management discussion and analysis, executive compensation, principal stockholders, underwriting, and legal matters. This type of document is a capital markets filing related to the company's fundraising and securities offering. It is not an annual report, earnings release, or any other report type but specifically a registration statement for a securities offering. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement or notice, so it is not RPA or RNS.
2014-08-11 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.